InvestorsHub Logo
Followers 4
Posts 1139
Boards Moderated 0
Alias Born 04/27/2006

Re: rod5247 post# 4944

Thursday, 11/24/2016 11:42:36 AM

Thursday, November 24, 2016 11:42:36 AM

Post# of 8833
"HER2 franchise Q3 2016
• Perjeta (+24%): Strong demand due to
neoadjuvant and mBC uptake in the EU
• Herceptin (+5%): Strong volume momentum
in the EU due to longer treatment duration
• Kadcyla (+5%): Growth driven by
International and Japan
Outlook 2016
• Herceptin: Further SC conversion
• Perjeta: Further increasing penetration
• APHINITY (adj BC) expected in Q1 2017

http://www.roche.com/dam/jcr:5a138f48-ffa8-4c34-8337-1045c7f12c0d/en/irp161020.pdf

Don't feed the troll.

Never argue with a fool, for after awhile, it becomes difficult to determine which is the fool.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News